Image Name

Enterprise News

Vcare 2024 Annual Review

Vcare 2024 Annual Review

Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises

Time：2025-01-27 18:01

Pan-Cancer Potential! Jiangsu Vcare’s Anti-Resistant TRK Inhibitor VC004 Capsule advances to NDA Preparation Phase

Pan-Cancer Potential! Jiangsu Vcare’s Anti-Resistant TRK Inhibitor VC004 Capsule advances to NDA Preparation Phase

In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.

Time：2025-01-26 18:06

Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing

Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group​​. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.

Time：2025-01-22 17:49

First dosing of patient in Phase III Clinical trial of Jiangsu Vcare's VC005 Tablets for Moderate-to-Severe Atopic Dermatitis

First dosing of patient in Phase III Clinical trial of Jiangsu Vcare's VC005 Tablets for Moderate-to-Severe Atopic Dermatitis

On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.

Time：2024-12-30 17:36

Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"

Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"

At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.

Time：2024-11-18 18:09

Jiangsu Vcare Approved to Establish "Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center"

Jiangsu Vcare Approved to Establish "Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center"

Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.

Time：2024-11-01 17:51

Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"

Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"

Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.

Time：2024-10-28 17:53

Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"

Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"

Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.

Time：2024-10-23 17:49

< 1234...10 >
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

SEO

Powerby：www.300.cn nanjing.300.cn